Use this url to cite publication: https://hdl.handle.net/20.500.12512/112019
Options
Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer
Type of publication
Straipsnis Web of Science duomenų bazėje / Article in Web of Science database (S1a)
Author(s)
Devos, Gaëtan | Leuven University Hospitals, Leuven, Belgium | KU Leuven, Leuven, Belgium |
Devlies, Wout | Leuven University Hospitals, Leuven, Belgium | KU Leuven, Leuven, Belgium |
de Meerleer, Gert | Leuven University Hospital, Radiation oncology, Leuven, Belgium | |
Baldewijns, Marcella | KU Leuven, Leuven, Belgium | |
Gevaert, Thomas | University Hospitals Leuven, Leuven, Belgium | |
Moris, Lisa | University Hospitals Leuven, Leuven, Belgium | KU Leuven, Leuven, Belgium |
University Hospitals Leuven, KU Leuven, Leuven, Belgium | ||
Van Poppel, Hendrik | University Hospitals Leuven, Department of Urology, Leuven, Belgium | |
Berghen, Charlien | University Hospitals Leuven, Leuven, Belgium | |
Everaerts, Wouter | University Hospitals Leuven, Leuven, Belgium | KU Leuven, Leuven, Belgium |
Claessens, Frank | KU Leuven, Leuven, Belgium | |
Joniau, Steven | University Hospitals Leuven, Leuven, Belgium | KU Leuven, Leuven, Belgium |
Title
Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer
Gaëtan Devos, Wout Devlies, Gert De Meerleer, Marcella Baldewijns, Thomas Gevaert, Lisa Moris, Daimantas Milonas, Hendrik Van Poppel, Charlien Berghen, Wouter Everaerts, Frank Claessens, Steven Joniau
Publisher (trusted)
Is Referenced by
Date Issued
Date Issued |
---|
2021-09-15 |
Extent
p. 739-762.
Is part of
Nature reviews. Urology. London : Nature Pub. Group, 2021, vol. 18, no. 12.
Version
Originalus / Original
Field of Science
Abstract
Patients with high-risk prostate cancer treated with curative intent are at an increased risk of biochemical recurrence, metastatic progression and cancer-related death compared with patients treated for low-risk or intermediate-risk disease. Thus, these patients often need multimodal therapy to achieve complete disease control. Over the past two decades, multiple studies on the use of neoadjuvant treatment have been performed using conventional androgen deprivation therapy, which comprises luteinizing hormone-releasing hormone agonists or antagonists and/or first-line anti-androgens. However, despite results from these studies demonstrating a reduction in positive surgical margins and tumour volume, no benefit has been observed in hard oncological end points, such as cancer-related death. The introduction of potent androgen receptor signalling inhibitors (ARSIs), such as abiraterone, apalutamide, enzalutamide and darolutamide, has led to a renewed interest in using neoadjuvant hormonal treatment in high-risk prostate cancer. The addition of ARSIs to androgen deprivation therapy has demonstrated substantial survival benefits in the metastatic castration-resistant, non-metastatic castration-resistant and metastatic hormone-sensitive settings. Intuitively, a similar survival effect can be expected when applying ARSIs as a neoadjuvant strategy in high-risk prostate cancer. Most studies on neoadjuvant ARSIs use a pathological end point as a surrogate for long-term oncological outcome. However, no consensus yet exists regarding the ideal definition of pathological response following neoadjuvant hormonal therapy and pathologists might encounter difficulties in determining pathological response in hormonally treated prostate specimens. The neoadjuvant setting also provides opportunities to gain insight into resistance mechanisms against neoadjuvant hormonal therapy and, consequently, to guide personalized therapy.
Type of document
type::text::journal::journal article
ISSN (of the container)
1759-4812
1759-4820
Other Identifier(s)
(LSMU ALMA)990001045990107106
Coverage Spatial
Jungtinė Karalystė / United Kingdom of Great Britain and Northern Ireland (GB)
Language
Anglų / English (en)
Bibliographic Details
225